Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$-0.67 → $-0.67 · observed estimates
CITIUS PHARMACEUTICALS INC (CTXR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.56+1.16%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CTXR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce net loss from -$28.1M in 2026-Q2 | A primary condition in CITIUS PHARMACEUTICALS INC's published investment case. The stated target is net loss less negative than -28.1 USD_MILLIONS. | Broken | Net loss worsens beyond -$28.1 million in next 4 quarters | Net income: $-11.919M FY2026-Q3; GAAP. Published target: net loss less negative than -28.1 USD_MILLIONS. Target period is not explicitly aligned with this observation. Aug 14, 2026-11,919,260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$-0.67 → $-0.67 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 22, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making biotechnology business with a launch-dependent growth thesis, not an established durable compounder. The long-term thesis is in a watch state: commercial activity is emerging, but recent financial performance is weak and management execution is described as volatile.
The valuation evidence points to CTXR being cheap versus peers, but confidence in that comparison is low. Valuation and composite insight have improved recently, while the available evidence does not show that the market assumes a specific level of future launch success.
Near term, the risk of another earnings miss is elevated, following recent misses and the October 26 earnings-miss event. LYMPHIR had revenue in the second quarter, and preliminary wholesaler unit sales rose in fiscal Q4, but finalized Q4 revenue is not provided; meanwhile, operating losses and cash use leave financing needs active.
Over the next several quarters, the key test is whether LYMPHIR’s launch activity produces sustained, reported revenue and whether the company can fund operations and commercialization. A guidance cut or continued weakness in economic data would add pressure, while strength among major healthcare companies could support the sector backdrop.
For the 1-to-3-year view, CTXR remains a high-risk, watch-stage thesis with early commercial activity but limited proof of financial follow-through. The central questions are revenue conversion, funding, and execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful M&A deals to strengthen the company | A supporting condition in CITIUS PHARMACEUTICALS INC's published investment case. The stated target is Active M&A engagement. | Under Pressure | No meaningful M&A activity in next 4 quarters | No M&A activity May 2026 event was a debt amendment, not M&A. No other M&A activity reported in the period. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $3.9 million in 2026 | A primary condition in CITIUS PHARMACEUTICALS INC's published investment case. The stated target is >=3.9 USD_MILLIONS. | Intact | Revenue falls below $3.9 million in FY26 | Revenue: $1.494M FY2026-Q3; GAAP. Published target: >=3.9 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 20261,493,788 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-02 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-03 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-04 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-05 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-06 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-07 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-08 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-09 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-10 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-11 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-12 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-13 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-14 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-15 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-16 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-17 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-18 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-19 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-20 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-21 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-22 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-23 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-24 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-25 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-26 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-27 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-28 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-29 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-30 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-10-31 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-11-01 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-11-02 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-11-03 | $-0.67 | $50,676,000 | 1 / 1 |
| 2026-11-04 | $-0.67 | $50,676,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.